Meeting
2018 Gastrointestinal Cancers Symposium
Outcomes and characteristics of patients receiving second-line therapy for advanced pancreatic cancer.
Authors
Erica S Tsang
BC Cancer Agency, Vancouver, BC, Canada
Erica S Tsang , Hui-Li Wong , Ying Wang , Daniel John Renouf , Winson Y. Cheung , Howard John Lim , Sharlene Gill , Jonathan M. Loree , Hagen F. Kennecke
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Multidisciplinary Treatment
Citation
J Clin Oncol 36, 2018 (suppl 4S; abstr 435)
DOI
10.1200/JCO.2018.36.4_suppl.435
Abstract #
435
Poster Bd #
L6
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Sequential first-line treatment with gemcitabine plus nab-paclitaxel (GA) followed by FOLFIRINOX (FFX) versus FFX alone in patients with metastatic pancreatic cancer (PC): GABRINOX-2 randomized phase 2 trial.
First Author: Fabienne Portales
Poster
2023 ASCO Gastrointestinal Cancers Symposium
First-line chemotherapy regimens associated with survival in advanced pancreatic cancer: A Mexican single-center, real-world study.
First Author: Marytere Herrera
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Efficacy of sequential perioperative FOLFIRNOX plus gemcitabine nab-paclitaxel for resected pancreatic and periampullary cancers.
First Author: Putao Cen
Poster
2021 ASCO Annual Meeting
Alternating gemcitabine/nab-paclitaxel (GA) and 5-FU/leucovorin/irinotecan (FOLFIRI) as first-line treatment for de novo metastatic pancreatic cancer (MPC): Safety and effect.
First Author: Brett A. Schroeder